These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18578093)

  • 1. Antiretroviral drug resistance in HIV-infected children: implications for long-term treatment.
    Tudor-Williams G; Green H
    J HIV Ther; 2007 Dec; 12(4):99-100. PubMed ID: 18578093
    [No Abstract]   [Full Text] [Related]  

  • 2. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.
    Hamers RL; Derdelinckx I; van Vugt M; Stevens W; Rinke de Wit TF; Schuurman R;
    Antivir Ther; 2008; 13(5):625-39. PubMed ID: 18771046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
    Koyalta D; Charpentier C; Beassamda J; Rey E; Si-Mohamed A; Djemadji-Oudjeil N; Bélec L
    Clin Infect Dis; 2009 Jul; 49(1):155-9. PubMed ID: 19480574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of antiretroviral resistance and impact on treatment outcomes.
    Cane P
    J HIV Ther; 2007 Dec; 12(4):82-4. PubMed ID: 18391892
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-resistant human immunodefiency virus.
    Kozal MJ
    Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral drug resistance testing: potential use following nosocomial exposure to HIV.
    Worthington M
    Clin Infect Dis; 2003 Dec; 37(12):1722-3. PubMed ID: 14689361
    [No Abstract]   [Full Text] [Related]  

  • 8. New horizons in antiretroviral drug resistance.
    Geretti AM
    J HIV Ther; 2007 Dec; 12(4):81-2. PubMed ID: 18391891
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.
    Moatti JP; N'Doye I; Hammer SM; Hale P; Kazatchkine M
    Nat Med; 2003 Dec; 9(12):1449-52. PubMed ID: 14647513
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral resistance in the developing world.
    Pillay D
    J HIV Ther; 2007 Dec; 12(4):95-6. PubMed ID: 18578091
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral rounds. Resistance: how do you know if you don't know?
    Campbell TB; Katzenstein D
    AIDS Clin Care; 2005 Mar; 17(3):26-7. PubMed ID: 15828117
    [No Abstract]   [Full Text] [Related]  

  • 13. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow accumulation of HIV resistance mutations: implications for resource-limited settings?
    Stevens WS
    J Infect Dis; 2009 Sep; 200(5):670-2. PubMed ID: 19604045
    [No Abstract]   [Full Text] [Related]  

  • 15. Choice of an initial antiretroviral regimen in the resource-limited setting: the cost of virologic failure.
    Campbell TB
    Clin Infect Dis; 2008 Sep; 47(5):723-5. PubMed ID: 18662135
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiretroviral therapy update. Everything you need to know, in a nutshell.
    Gallant J
    Posit Aware; 2008; 19(1):10-3. PubMed ID: 18546575
    [No Abstract]   [Full Text] [Related]  

  • 17. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline watch. Antiretroviral drug resistance testing--updated guidelines from the IAS-USA.
    Hicks CB
    AIDS Clin Care; 2008 Aug; 20(8):64. PubMed ID: 18814369
    [No Abstract]   [Full Text] [Related]  

  • 19. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prison study shows a transmission first. Finding supports need for consistent meds use.
    AIDS Alert; 2001 Feb; 16(2):24-5. PubMed ID: 15446223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.